Haploidentical Transplants for Myeloproliferative Neoplasms

  • Monzr M. Al Malki
  • Stefan O. Ciurea
  • Richard E. Champlin
Part of the Advances and Controversies in Hematopoietic Transplantation and Cell Therapy book series (ACHTCT)


Allogeneic hematopoietic cell transplantation remains the only curative therapy available for patients with myeloproliferative neoplasms and is mostly performed for primary myelofibrosis or secondary myelofibrosis with high dynamic international scoring system-plus score, advanced (or refractory) chronic myelogenous leukemia, and chronic myelomonocytic leukemia, traditionally with HLA-matched donors. The outcomes for chronic myelogenous leukemia with HLA-matched unrelated donors may be similar with HLA-matched sibling donor transplants; outcomes for other MPNs may not be the same. In the setting of HLA-matched unrelated donors, the results with busulfan-based conditioning for patients with myelofibrosis are encouraging. Multiple single institution and registry studies have shown safety of haploidentical transplants with comparable outcomes as HLA-matched transplants. All studies so far have shown lower incidence of acute and chronic GvHD with comparable treatment-related mortality to HLA-matched unrelated transplants. In this chapter, we will review the strengths and weaknesses of different platforms using HLA-haploidentical-matched donors for chronic myelogenous leukemia and myelofibrosis.


Haploidentical transplants Myelofibrosis (MPN) Myeloproliferative neoplasms GvHD Relapse Conditioning CML 


  1. 1.
    Vardiman J, Hyjek E. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Hematology Am Soc Hematol Educ Program. 2011;2011:250–6.PubMedGoogle Scholar
  2. 2.
    Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant. 2007;13:64–72.CrossRefGoogle Scholar
  3. 3.
    Adekola K, Popat U, Ciurea SO. An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors. Bone Marrow Transplant. 2014;49:1352–9.CrossRefGoogle Scholar
  4. 4.
    Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831–8.PubMedGoogle Scholar
  5. 5.
    Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255–8.CrossRefGoogle Scholar
  6. 6.
    Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912–8.CrossRefGoogle Scholar
  7. 7.
    Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128:690–7.CrossRefGoogle Scholar
  8. 8.
    Snyder DS, Palmer J, Gaal K, et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant. 2010;16:281–6.CrossRefGoogle Scholar
  9. 9.
    Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339–48.CrossRefGoogle Scholar
  10. 10.
    Ciurea SO, Bayraktar UD. “No donor”? Consider a haploidentical transplant. Blood Rev. 2015;29:63–70.CrossRefGoogle Scholar
  11. 11.
    Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105:4115–9.CrossRefGoogle Scholar
  12. 12.
    Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124:1183–91.CrossRefGoogle Scholar
  13. 13.
    Murata M, Nishida T, Taniguchi S, et al. Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT. Bone Marrow Transplant. 2014;49:355–60.CrossRefGoogle Scholar
  14. 14.
    Robin M, Giannotti F, Deconinck E, et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2014;20:1841–6.CrossRefGoogle Scholar
  15. 15.
    Ohashi K, Nagamura-Inoue T, Nagamura F, et al. Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. Int J Hematol. 2014;100:296–306.CrossRefGoogle Scholar
  16. 16.
    Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.CrossRefGoogle Scholar
  17. 17.
    Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1835–44.CrossRefGoogle Scholar
  18. 18.
    Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–22.CrossRefGoogle Scholar
  19. 19.
    Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–6.CrossRefGoogle Scholar
  20. 20.
    Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975–81.CrossRefGoogle Scholar
  21. 21.
    Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20:1573–9.CrossRefGoogle Scholar
  22. 22.
    Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–40.CrossRefGoogle Scholar
  23. 23.
    Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med. 2008;40:444–55.CrossRefGoogle Scholar
  24. 24.
    Zhao XY, Chang YJ, Xu LP, et al. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients. Br J Cancer. 2014;111:1080–8.CrossRefGoogle Scholar
  25. 25.
    Xu L, Xu Z, Zhang X, Chen H, Chen Y, Huang X. Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia. Bone Marrow Transplant. 2016;51:S158–S9.Google Scholar
  26. 26.
    Ma YR, Huang XJ, Xu ZL, et al. Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clin Transplant. 2016;30:994–1001.CrossRefGoogle Scholar
  27. 27.
    Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017;31(7):1654–7. Epub 2017 Apr 12.CrossRefPubMedGoogle Scholar
  28. 28.
    Bregante S, Dominietto A, Ghiso A, et al. Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors. Biol Blood Marrow Transplant. 2016;22:324–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Monzr M. Al Malki
    • 1
  • Stefan O. Ciurea
    • 2
  • Richard E. Champlin
    • 2
  1. 1.City of Hope National Medical CenterDuarteUSA
  2. 2.Department of Stem cell Transplantation and Cellular TherapyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations